EVALUATION OF THE COST EFFECTIVENESS OF THE TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE IN BRAZIL
Author(s)
da Silva LR
Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES: The study aims to evaluate the cost effectiveness of donepezil versus rivastigmine of treating mild to moderate Alzheimer’s disease (AD) in Brazil by considering correlated changes in cognition, neuropsychiatrics symptoms and comorbities. CONCLUSIONS: The cost effectiveness study results suggest that donepezil may be cost effective in patients with mild to moderate Alzheimer's Disease in Brazil.
METHODS: A Markov Model was created to characterize disease progression among patients in the mild to moderate stage as well as the cost of health care for the patient analyzed. The rate of disease progression was modeled using data from population-based studies, clinical trials and studies based on economic modeling applied evaluation of pharmacological treatment of AD. Data on the costs and resources for the treatment of disease were removed from national databases. As effectiveness measure was decided to use Quality-adjusted life-year (QALY).
RESULTS: For mild to moderately AD, the results of the study suggested that the two treatments were beneficial when assessed using cognitive outcome measures. The treatment with donepezi was associated with the increase in QALYs of 0,036 followed by rivastigmin with an increase of 0,037. The annual cost per patient ranges from $11.000,00 with donepezil to $31.000,00 with rivastigmine. Taking into account the effectiveness and direct cost of the two treatments the cost effectiveness analysis points that donepezil dominates rivastigmine.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PND25
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Neurological Disorders